OMERS ADMINISTRATION Corp Takes $374,000 Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

OMERS ADMINISTRATION Corp purchased a new position in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 116,900 shares of the company's stock, valued at approximately $374,000. OMERS ADMINISTRATION Corp owned 0.24% of Checkpoint Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of the business. SBI Securities Co. Ltd. bought a new position in Checkpoint Therapeutics during the 4th quarter worth $32,000. Tower Research Capital LLC TRC increased its stake in shares of Checkpoint Therapeutics by 157.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock valued at $34,000 after buying an additional 6,486 shares during the period. Virtu Financial LLC raised its position in shares of Checkpoint Therapeutics by 180.5% during the fourth quarter. Virtu Financial LLC now owns 38,157 shares of the company's stock worth $122,000 after acquiring an additional 24,552 shares during the last quarter. Stifel Financial Corp acquired a new position in shares of Checkpoint Therapeutics in the fourth quarter worth approximately $32,000. Finally, Raymond James Financial Inc. bought a new stake in Checkpoint Therapeutics in the fourth quarter valued at approximately $67,000. Institutional investors own 22.00% of the company's stock.

Insider Activity at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 15,090 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $4.04, for a total transaction of $60,963.60. Following the transaction, the chief executive officer now owns 3,759,929 shares of the company's stock, valued at $15,190,113.16. This represents a 0.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO William Garrett Gray sold 12,322 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the completion of the sale, the chief financial officer now owns 1,446,322 shares of the company's stock, valued at approximately $5,857,604.10. This represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.10% of the stock is owned by corporate insiders.

Checkpoint Therapeutics Price Performance

NASDAQ CKPT opened at $4.16 on Tuesday. The stock has a market capitalization of $348.46 million, a P/E ratio of -2.26 and a beta of 1.18. The business has a 50 day simple moving average of $4.06 and a 200 day simple moving average of $3.63. Checkpoint Therapeutics, Inc. has a one year low of $1.75 and a one year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.09). Equities analysts expect that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on CKPT shares. D. Boral Capital restated a "buy" rating and set a $4.80 price target on shares of Checkpoint Therapeutics in a report on Monday, March 31st. Lake Street Capital reiterated a "hold" rating and set a $4.10 price objective (down from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. Finally, HC Wainwright restated a "neutral" rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

Want to see what other hedge funds are holding CKPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.